导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.31% | 4054/4773 |
| 近一周 | -4.75% | 5273/5467 |
| 近一月 | -4.84% | 1971/5421 |
| 近一季 | -4.40% | 1609/5238 |
| 近半年 | -6.19% | 3276/4931 |
| 近一年 | -16.53% | 3785/4400 |
| 近两年 | 32.13% | 2181/2954 |
| 近三年 | 10.89% | 1725/2253 |
| 成立以来 | 18.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-16.07% 4739/4961 |
11.14% 2367/5312 |
- - |
- - |
| 2025 | 6.05% 2976/4813 |
-6.87% 3407/3635 |
5.02% 660/4076 |
11.86% 3121/4524 |
-3.06% 3247/4813 |
| 2024 | 31.01% 104/3463 |
-4.29% 1633/2808 |
-8.18% 2178/3014 |
42.97% 30/3129 |
4.27% 726/3463 |
| 2023 | 0.95% 382/2656 |
3.65% 1155/2280 |
-2.36% 585/2385 |
6.01% 80/2515 |
-5.90% 1548/2655 |
| 2022 | -25.34% 1311/2207 |
-18.87% 1408/1919 |
3.07% 1219/2016 |
-17.11% 1555/2113 |
7.72% 294/2208 |
| 2021 | 1.55% 666/1822 |
-13.18% 1155/1255 |
8.31% 637/1330 |
6.00% 246/1466 |
1.88% 765/1822 |
| 2020 | 23.01% 660/1250 |
-9.20% 663/1028 |
11.03% 750/1067 |
20.06% 62/1164 |
1.62% 1021/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华国证证券龙头ETF VS. 长安沪深300非周期A(740101) |